<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045665</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1078</org_study_id>
    <secondary_id>2U01HL088942-12</secondary_id>
    <nct_id>NCT04045665</nct_id>
  </id_info>
  <brief_title>Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG</brief_title>
  <acronym>PACES</acronym>
  <official_title>Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effectiveness (prevention of
      thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to
      background antiplatelet therapy in patients who develop new-onset post-operative atrial
      fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.

      All patients with a qualifying POAF event, who decline randomization, will be offered the
      option of enrollment in a parallel registry that captures their baseline risk profile and
      their treatment strategy in terms of anticoagulants or antiplatelets received. These patients
      will also be asked to fill out a brief decliner survey.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, open-label, randomized trial comparing OAC with no OAC
      (1:1 ratio) in patients who develop new-onset POAF after CABG. The primary effectiveness
      endpoint is the composite of death, stroke, transient ischemic attack (TIA), myocardial
      infarction (MI), systemic arterial thromboembolism or venous thromboembolism (VTE) at 90 days
      after randomization. The primary safety endpoint is BARC (Bleeding Academic Research
      Consortium) grade 3 or 5 bleeding at 90 days after randomization. The overall intent is to
      evaluate the trade-off in prevention of thromboembolic events versus an increase in bleeding.

      Patients will be randomly assigned to the following treatment strategies:

        -  OAC-based strategy (experimental arm): OAC with vitamin K antagonist (VKA) with
           international normalized ratio (INR) target 2-3 or any approved direct oral
           anticoagulant (apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background
           antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel
           or ticagrelor)

        -  Antiplatelet-only strategy (control arm): with aspirin 75-325mg once-daily or a
           P2Y12-inhibitor (clopidogrel or ticagrelor)

      The protocol-specified duration of anticoagulation is 90 days. Patients, who are randomized
      to the control arm and develop recurrent AF after 30 days, may be crossed-over to an OAC.
      Accrual is expected to take 36 months. Study follow-up visits will be performed at 90 days
      and phone follow-up at 180 days.

      Data for patients enrolled in the registry will be ascertained from the local clinical site
      via a review of medical records. The baseline risk profile of registry patients (i.e.,
      patients eligible but unwilling to be randomized) will be analyzed and compared to that of
      patients randomized in the trial. The usage of anticoagulant and antiplatelet therapies in
      the registry population overall and baseline CHA2DS2-VASC stroke risk score will also be
      determined.

      Patients will be offered the option of having biospecimens collected for future research.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicenter randomized clinical trial comparing OAC to no-OAC in addition to concomitant antiplatelet therapy in 3,200 eligible patients who develop POAF after isolated CABG. The trial will be conducted by the Cardiothoracic Surgical Trials Network (CTSN), the German Society for Thoracic and Cardiovascular Surgery (DGTHG) and other European sites.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of death, stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE)</measure>
    <time_frame>up to 180 days after randomization</time_frame>
    <description>Composite score of death, stroke, transient ischemic attack (TIA), myocardial infarction (MI), systemic arterial thromboembolism or venous thromboembolism (deep venous thrombosis and/or pulmonary embolism). Composite score calculated by number of events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any BARC type 3 or 5</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>The Bleeding Academic Research Consortium (BARC) - any type 3 or 5 bleeding thrombosis and/or pulmonary.
Type 3: a. Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding
b. Overt bleeding plus hemoglobin drop &lt; 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents
c. Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision.
type 5: a. Probable fatal bleeding
b. Definite fatal bleeding (overt or autopsy or imaging confirmation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Net clinical benefit (NCB)</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Defined as the integration of the trial's primary effectiveness and safety endpoint to capture overall risk and benefit of anticoagulation. NCB will be assessed as a two-dimensional outcome with the observed NCB plotted versus effectiveness and safety, and a curve drawn. the confidence intervals will be compared to this curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Stroke event</measure>
    <time_frame>180 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TIA event</measure>
    <time_frame>180 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with MI event</measure>
    <time_frame>180 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with systematic arterial thromboembolism event</measure>
    <time_frame>180 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with venous thromboembolism event</measure>
    <time_frame>180 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cardiovascular mortalities</measure>
    <time_frame>up to 180 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-cardiovascular mortalities</measure>
    <time_frame>up to 180 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of BARC 2 bleeding at 90 days after randomization</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>BARC Type 2: Any clinically overt sign of hemorrhage that &quot;is actionable&quot; and requires diagnostic studies, hospitalization, or treatment by a health care professional</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cardiac arrhythmias</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Number of cardiac arrhythmias including recurrent symptomatic AF requiring medical attention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Antiplatelet Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiplatelet-only strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Anticoagulant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OAC-based strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet-only strategy</intervention_name>
    <description>Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)</description>
    <arm_group_label>Antiplatelet Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Anticoagulant plus background antiplatelet therapy</intervention_name>
    <description>OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)</description>
    <arm_group_label>Oral Anticoagulant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of age ≥18 years who undergo isolated CABG for coronary artery disease

          -  POAF that persists for &gt;60 minutes or is recurrent (more than one episode) within 7
             days after the index CABG surgery

        Exclusion Criteria:

          -  Clinical history of either permanent, persistent or paroxysmal atrial fibrillation

          -  Any pre-existing clinical indication for long-term OAC

          -  Any absolute contraindication to OAC

          -  Planned use of post-operative dual antiplatelet therapy (DAPT)

             a. This includes, but is not limited to, patients with recent PCI with drug-eluting or
             bare-metal stent.

          -  Cardiogenic shock

          -  Major perioperative complication* occurring between CABG and randomization

             a. Including stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis,
             renal failure requiring dialysis, or need for reoperation due to bleeding (e.g.
             pericardial tamponade).

          -  Concomitant left atrial appendage closure during CABG

          -  Concomitant valve surgery during CABG (including aortic, mitral, tricuspid or
             pulmonary)

          -  Concomitant or prior surgery for AF during CABG

          -  Closure of an atrial septal defect or of a patent foramen ovale during CABG

          -  Stage IV or V chronic kidney disease (estimated glomerular filtration rate [eGFR]&lt;30
             mL/min/1.73m2)

          -  Liver cirrhosis or Child-Pugh Class C chronic liver disease

          -  Pharmacologic therapy with an investigational drug or device within 30-days prior to
             randomization or plan to enroll patient in an investigational drug or device trial
             during participation in this trial

          -  Pregnancy at the time of randomization

          -  Unable or unwilling to provide inform consent

          -  Unable or unwilling to comply with the study treatment and follow-up

          -  Existence of underlying disease that limits life expectancy to less than one year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annetine C Gelijns, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Gillinov, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Alexander, MD</last_name>
    <role>Study Director</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Moquete, RN</last_name>
    <phone>212-659-9651</phone>
    <email>ellen.moquete@mountsinai.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHI St. Vincent, Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Stocks</last_name>
      <email>sstocks@heartclinicarkansas.com</email>
    </contact>
    <investigator>
      <last_name>Thurston Bauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ed Lozano</last_name>
      <email>edwardlo@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Bowdish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicholas Vesom</last_name>
      <email>nvesom@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Woo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Hospital Systems</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MarieElena Cordisco</last_name>
      <email>marieelena.cordisco@wchn.org</email>
    </contact>
    <investigator>
      <last_name>Robert Gallagher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne McCarthy</last_name>
      <email>marianne.mccarthy@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Arnar Geirsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chari Ponder</last_name>
      <email>chari.ponder@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Halkos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lutheran Medical Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Eichman</last_name>
      <email>SEichman@Lutheran-Hosp.com</email>
    </contact>
    <investigator>
      <last_name>Vincent Scavo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Broach</last_name>
      <email>dbroach@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Lawrence Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Laudun</last_name>
      <phone>504-842-3722</phone>
      <email>slaudun@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>P. Eugene Parrino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsey Gallant</last_name>
      <email>bgallant@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Kramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manal Al-Suqi</last_name>
      <email>MaAl-Suqi@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>James Gammie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Greenberg</last_name>
      <email>agreen64@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Siegenthaler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward Percy</last_name>
      <email>epercy@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Pelletier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janell Keehn</last_name>
      <email>keehn.janell@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Juan Crestanello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid America Health Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie M Hayes</last_name>
      <email>nhayes@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Keith Allen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hank Stokes</last_name>
      <email>henry.c.stokes@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Alex Iribarne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health System</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Effe Mihelis</last_name>
      <email>emihelis@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Nirav Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stella Palencia</last_name>
      <email>Stella.Palencia@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>John Puskas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Persaud</last_name>
      <email>ns3125@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Argenziano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Lane</last_name>
      <email>kathleen.rohrback@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Peter K. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Bremer</last_name>
      <email>bremerj17@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Shahab A. Akhter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WakeMed</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhonda Norton</last_name>
      <email>rnorton@wakemed.org</email>
    </contact>
    <investigator>
      <last_name>Judson Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Kosty-Sweeney</last_name>
      <email>sweened2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>A Marc Gillinov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shawna Oxier</last_name>
      <email>shawna.oxier@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bryan Whitson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Hermitage</city>
        <state>Pennsylvania</state>
        <zip>16148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Enlow</last_name>
      <email>enlowms@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Kormos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Lou Mayer</last_name>
      <email>MaryLou.Mayer@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Acker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather McDonald</last_name>
      <email>heather.mcdonald@ahn.org</email>
    </contact>
    <investigator>
      <last_name>M. Scott Halbreiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen de la Penha</last_name>
      <email>penha@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Rosengart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Chionh</last_name>
      <email>Kristen.Chionh@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Mack</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Lawson</last_name>
      <email>Scott.Lawson@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Selzman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Cosner</last_name>
      <email>jmc2cm@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Gorav Ailawadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Health</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Saulino</last_name>
      <email>patricia.saulino@inova.org</email>
    </contact>
    <investigator>
      <last_name>Eric Sarin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Fornaresio</last_name>
      <email>lisa.fornaresio@wvumedicine.org</email>
    </contact>
    <investigator>
      <last_name>Vinay Badhwar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaelin Grant</last_name>
      <email>grantk@surgery.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Malcolm McAvoy DeCamp, Jr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kayla-Marie Smith</last_name>
      <email>kaylamar@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>John Mullen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Fox</last_name>
      <email>Stephanie.Fox@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Fortier</last_name>
      <email>JFortier@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Marc Ruel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reena Karkhanis</last_name>
      <email>Reena.Karkhanis@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Fremes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shakira Christie</last_name>
      <email>Shakira.Christie@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Terrance Yau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steeve Greniere</last_name>
      <email>Steeve.Grenier@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Louis Perrault</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joannie Dionne</last_name>
      <email>joannie.dionne.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Nicolas Noiseux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole Sirois</last_name>
      <email>carole.sirois@crhsc.rtss.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Hugues Jeanmart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Gagne</last_name>
      <email>Nathalie.Gagne@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Pierre Voisine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>11353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jutta Nogal</last_name>
      <email>j.nogal@uke.de</email>
    </contact>
    <investigator>
      <last_name>Lennard Conradi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robby Schurzmann</last_name>
      <email>robby.schurzmann@leipzig-heart.de</email>
    </contact>
    <investigator>
      <last_name>Bettina Pfannmuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessika Jordan</last_name>
      <email>jessika.jordan@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Bernd Danner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Krauspe</last_name>
      <email>sabine.krauspe@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Torsten Doenst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic Bad Neustadt - Medical Center for Heart and Vascular Diseases</name>
      <address>
        <city>Bad Neustadt An Der Saale</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katharina Schoenrath</last_name>
      <email>kschoenrath@dhzb.de</email>
    </contact>
    <investigator>
      <last_name>Anno Diegeler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HDZ-NRW Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heike Windhagen</last_name>
      <email>ch-studien@dhz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Kavous Hakim-Meibodi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Berlin - Benjamin Franklin Campus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulf Landmesser, MD</last_name>
      <email>ulf.landmesser@charite.de</email>
    </contact>
    <investigator>
      <last_name>Ulf Landmesser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Berlin - Rudolf Virchow Campus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Burkert Pieske, MD</last_name>
      <email>burkert.pieske@charite.de</email>
    </contact>
    <investigator>
      <last_name>Burkert Pieske, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Heart Center Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doris Pickel</last_name>
      <email>pickel@dhzb.de</email>
    </contact>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yessica Peglau</last_name>
      <email>j.peglau@klinikum-braunschweig.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Harringer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heike Strohschnitter</last_name>
      <email>Heike.Strohschnitter@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Walther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Blümel, MD</last_name>
      <email>veronika.bluemel@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Friedhelm Beyersdorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane Miesel-Groeschel</last_name>
    </contact>
    <investigator>
      <last_name>Gábor Szabó, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beke Sarrahs</last_name>
      <email>beke.sarrahs@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Assad Haneya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessika Schmidt</last_name>
      <email>jessika.schmidt@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Klotz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Heart Center Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephani Simon</last_name>
      <email>simons@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Markus Krane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Ludwig-Maximilians-University Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Hagl, MD</last_name>
      <email>christian.hagl@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Hagl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ctsurgerynet.org/index.html</url>
    <description>The Cardiothoracic Surgical Trials Network</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Annetine Gelijns</investigator_full_name>
    <investigator_title>Chair, Department of Population Health Science &amp; Policy Edmond A. Guggenheim Professor of Health Policy Co-Director, InCHOIR</investigator_title>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>Antiplatelet Therapy</keyword>
  <keyword>Post Operative Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>OtherDe-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data.Any purpose.Data are available indefinitely at (Link to be included).</ipd_access_criteria>
    <ipd_url>https://biolincc.nhlbi.nih.gov/studies/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

